Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Promedior, a biopharmaceutical company, has appointed Dominick Colangelo as its new CEO and a member of the company's board of directors. Mr Colangelo succeeds Tim Pelura, who will assume a new role as chief scientific officer of the company.
Subscribe to our email newsletter
Mr Colangelo joins Promedior after a nearly 15-year pharmaceutical industry career at Eli Lilly and Company and most recently as executive vice president of corporate development and operations at Oscient Pharmaceuticals.
Mr Colangelo holds a BSBA in accounting from the State University of New York at Buffalo and a JD degree from the Duke University School of Law.
Joseph Zakrzewski, chairman of board of directors of Promedior, said: “Nick brings a tremendous amount of corporate development, commercial, and pharmaceutical operations experience to Promedior. He is ideally suited to lead Promedior’s next stage of growth as the company prepares to begin clinical development of its lead product candidate.”